International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain

Summary

Stocks of the International Reference Preparation (IRP) for thromboplastin, human, plain, coded BCT/253 and held by the World Health Organization (WHO) are nearly exhausted and must be replaced. For practical reasons the choice of the replacement candidate was restricted to two available human recombinant preparations which were coded as X/95 and Y/95 and calibrated in an international collaborative study involving 19 laboratories from Europe, Australia, Canada and Argentina. To minimize the differences between routes of calibration, the two candidates were calibrated against the existing WHO-IRP from human, rabbit and bovine origin and the final ISI was the resultant average value. On the basis of predefined criteria (i.e., within- and between-laboratory precision of the calibration and the conformity to the calibration model), X/95 was the preferred candidate. The assigned ISI (SE of the mean) value is 0.940 (0.0060) and the interlaboratory coefficient of variation 4.7%.

• References

• 1 WHO Expert Committee on biological Standardization. 33th Report, Tech Rep Ser 1983; 687: 81, Geneva.
• 2 van den Besselaar AMHP. Multicenter study of replacement of the international reference preparation for thromboplastin, rabbit, plain. Thromb Haemost 1993; 70: 794-9.
• 3 Hermans J, van den Besselaar AMHP, Loeliger EA, van der Velde EA. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost 1983; 50: 712-7.
• 4 Thomson JM, Tomenson JA, Poller L. The calibration of the second primary international reference preparation for thromboplastin (thromboplastin, human, plain, coded BCT/253). Thromb Haemost 1984; 52: 336-42.
• 5 Reijnierse GLA, van den Besselaar AMHP, Hermans J. Een nieuw verwerkings programma van ingezonden uitslagen in het kader van externe kwailiteisbewaking. Ervaringen in 1988. Tijdschr NVKC 1989; 14: 131-6.
• 6 Tomenson JA. A statistician’s independent evaluation. In: Thromboplastin calibration. van den Besselaar AMHP, Gralnick HR, Lewis SM. (eds). Martinus Nijhoff Publishers; Boston: 1984. pp 87-108.
• 7 World Health Organization.. Recommended methodology for using WHO International Reference Preparations for thromboplastins. WHO, 1211 Geneva 27, Switzerland.
• 8 Tripodi A, Poller L, van den Besselaar AMHP, Mannucci PM. A proposed scheme for calibration of international reference preparations of thromboplastin for the prothrombin time. Thromb Haemost 1995; 74: 1368-9.
• 9 Tripodi A, Chantarangkul V, Braga M, Poller L, ten Cate JW, van den Besselaar AMHP, Mannucci PM. Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thromb Haemost 1994; 72: 261-7.
• 10 Bader R, Mannucci PM, Tripodi A, Hirsh J, Keller F, Solleder EM, Hawkins P, Peng M, Pelzer H, Teijidor LM, Ramirez IF, Kolde HJ. Multicenter evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost 1994; 71: 292-9.
• 11 Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH).. Report of Subcommittee on Control of Anticoagulation. (Chair, T.W. Barrowcliffe). 22-24 June 1996, Barcelona (Spain).